WO2010146595A3 - Novel polymorphs of flibanserin hydrochloride - Google Patents

Novel polymorphs of flibanserin hydrochloride Download PDF

Info

Publication number
WO2010146595A3
WO2010146595A3 PCT/IN2009/000347 IN2009000347W WO2010146595A3 WO 2010146595 A3 WO2010146595 A3 WO 2010146595A3 IN 2009000347 W IN2009000347 W IN 2009000347W WO 2010146595 A3 WO2010146595 A3 WO 2010146595A3
Authority
WO
WIPO (PCT)
Prior art keywords
hemihydrate
flibanserin hydrochloride
novel polymorphs
anhydrous
flibanserin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2009/000347
Other languages
French (fr)
Other versions
WO2010146595A2 (en
Inventor
Dodda Mohan Rao
Pingili Krishna Reddy
Buthukuri Venkat Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symed Labs Ltd
Original Assignee
Symed Labs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symed Labs Ltd filed Critical Symed Labs Ltd
Priority to PCT/IN2009/000347 priority Critical patent/WO2010146595A2/en
Publication of WO2010146595A2 publication Critical patent/WO2010146595A2/en
Anticipated expiration legal-status Critical
Publication of WO2010146595A3 publication Critical patent/WO2010146595A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides novel crystalline anhydrous form II, hemihydrate form III, anhydrous form IV, anhydrous form V, anhydrous form VI, hemihydrate form VII, hemihydrate form VIII, hemihydrate form IX and amorphous form of flibanserin hydrochloride, processes for its preparation and to pharmaceutical compositions containing them.
PCT/IN2009/000347 2009-06-16 2009-06-16 Novel polymorphs of flibanserin hydrochloride Ceased WO2010146595A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2009/000347 WO2010146595A2 (en) 2009-06-16 2009-06-16 Novel polymorphs of flibanserin hydrochloride

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2009/000347 WO2010146595A2 (en) 2009-06-16 2009-06-16 Novel polymorphs of flibanserin hydrochloride

Publications (2)

Publication Number Publication Date
WO2010146595A2 WO2010146595A2 (en) 2010-12-23
WO2010146595A3 true WO2010146595A3 (en) 2013-02-07

Family

ID=43356830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000347 Ceased WO2010146595A2 (en) 2009-06-16 2009-06-16 Novel polymorphs of flibanserin hydrochloride

Country Status (1)

Country Link
WO (1) WO2010146595A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017055935A1 (en) * 2015-09-30 2017-04-06 Symed Labs Limited Amorphous co-precipitates of flibanserin
WO2017076356A1 (en) * 2015-11-05 2017-05-11 苏州晶云药物科技有限公司 Novel crystal form of flibaserin, and preparation method therefor
CN106866546A (en) * 2015-12-10 2017-06-20 常州爱诺新睿医药技术有限公司 Solid dispersions of flibanserin or its pharmaceutically acceptable salt and pharmaceutic adjuvant and preparation method thereof
CN108699007A (en) * 2016-01-31 2018-10-23 孟晓明 New crystal form of flibanserin and its preparation method and use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576318A (en) * 1991-07-30 1996-11-19 Boehringer Ingelheim Italia S.P.A. Benzimidazolone derivatives
WO2003013539A1 (en) * 2001-08-10 2003-02-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neuroprotective drug
WO2006119958A2 (en) * 2005-05-13 2006-11-16 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of chronic pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576318A (en) * 1991-07-30 1996-11-19 Boehringer Ingelheim Italia S.P.A. Benzimidazolone derivatives
WO2003013539A1 (en) * 2001-08-10 2003-02-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neuroprotective drug
WO2006119958A2 (en) * 2005-05-13 2006-11-16 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of chronic pain

Also Published As

Publication number Publication date
WO2010146595A2 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
WO2010092090A3 (en) Novel salts of sitagliptin
WO2010139981A3 (en) Processes for preparing crystalline forms of dasatinib
WO2011098582A3 (en) Novel crystalline forms of ivabradine hydrochloride
WO2009104021A3 (en) Novel polymorphs and processes for their preparation
EA201171151A1 (en) CRYSTALLINE TRIPEPTIDE EPOXYKETON-PROTEASE INHIBITORS
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
WO2010139979A3 (en) Processes for preparing crystalline forms of dasatinib
IN2012DN01292A (en)
WO2012015681A3 (en) Drug-ligand conjugates, synthesis thereof, and intermediates thereto
WO2012015999A3 (en) Process for the preparation of imatinib mesylate
WO2010049449A3 (en) Novel salts of sunitinib
EP2216333A3 (en) Crystalline forms of Dexlansoprazole
WO2010008735A3 (en) Solid states of o-desmethylvenlaf axine salts
WO2010129636A3 (en) Lenalidomide polymorph
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2010079045A3 (en) Crystalline salt forms of flibanserine
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
WO2010131035A8 (en) Novel crystalline polymorph of sitagliptin dihydrogen phosphate
WO2010146595A3 (en) Novel polymorphs of flibanserin hydrochloride
WO2010027848A3 (en) Forms of lapatinib compounds and processes for the preparation thereof
WO2011058524A3 (en) Crystalline forms of bosentan salts and processes for their preparation
AP2012006280A0 (en) Synthesis process, and crystalline form of 4-ä3-ÄCis-hexahydrocyclopentaÄCÜpyrrol-2(1H)-YLÜpropoxyübenzamide hydrochloride and pharmaceutical compositions containing it.
PH12013500210A1 (en) Highly crystalline valsartan
WO2010061220A3 (en) Novel processes and pure polymorphs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09846109

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09846109

Country of ref document: EP

Kind code of ref document: A2